Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583729 | 0.99 | RAB9A (0.46) | RAB9ANPC1CTDSP1SMN1; SMN2MEN1 | |
| SCHEMBL20583499 | 0.96 | RAB9A (0.46) | RAB9ANPC1CTDSP1SMN1; SMN2MEN1 | |
| SCHEMBL20583565 | 0.88 | CCR2 (0.40) | RAB9ANPC1CTDSP1SMN1; SMN2MEN1 | |
| SCHEMBL8174021 | 0.77 | MEN1 (0.53) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL8180307 | 0.77 | LMNA (0.50) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8173186 | 0.75 | POLB (0.50) | RAB9ANPC1CTDSP1SMN1; SMN2MEN1 | |
| SCHEMBL8180075 | 0.73 | NPC1 (0.60) | RAB9ANPC1CTDSP1SMN1; SMN2MEN1 | |
| SCHEMBL26110369 | 0.72 | SMN1; SMN2 (0.46) | RAB9ANPC1CTDSP1SMN1; SMN2KMT2A | |
| SCHEMBL20583509 | 0.72 | SMN1; SMN2 (0.46) | RAB9ANPC1CTDSP1SMN1; SMN2KMT2A | |
| SCHEMBL8167085 | 0.72 | EPHX2 (0.51) | RAB9ANPC1CTDSP1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| CN-114716381-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114634447-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114621146-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114605327-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114591242-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114573510-A | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3782994-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Loxo Oncology, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10918622-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3390395-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10695323-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10464905-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10342780-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20180362512-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20190135762-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-10918622-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20200276162-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-10695323-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-10464905-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-10342780-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | RAB9A 2532/4885NPC1 3295/4885CTDSP1 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.